Sagimet Biosciences Inc.
SGMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from. With a market capitalization of $482.9M, it sits in small-cap territory. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Market Cap
$482.9M
Beta
3.38
P/E (TTM)
—
P/E (Fwd)
-5.96
EPS (TTM)
$-1.38
EPS (Fwd)
$-1.31
ROE
-36.0%
ROA
-24.0%
Cash
$104.5M
Total Debt
$39,000
Free CF
-$27.2M
52W Change
-16.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $104.5M in cash comfortably exceeding the $39K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$27.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -36.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Sagimet Biosciences Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sagimet Biosciences Inc. and its sector.